

REMARKS:

Claims 2 and 15-17 are in the case and presented for reconsideration.

Claims 2 and 15-17 were rejected under 35 U.S.C. § 102(b) as being anticipated by Kampe et al. (US Patent 3,551,409).

Claim 2 has been amended to eliminate the compounds disclosed in Kampe et al. so that claim 2, and its dependent claims 15-17, are now believed to be allowable.

Specifically, the compounds bearing hydroxy and halogen substituents in position 2 of the purine ring have been deleted from claim 2.

Kampe teaches adenosine derivatives bearing hydroxyl or halogen substituents in position 2 of the purine structure, and provides also for the substituted benzylamino group in position 6 of the purine skeleton. These compounds possess hemodynamic and coronary dynamic activity. In col. 16, Kampe also mentions the administration of the adenosine derivatives in the form of thir solutions or suspensions. Accordingly, in order to overcome the teaching of Kampe as cited by the Examiner, the compounds having hydroxy or halogen substituents in position 2 of the purine structure were deleted from the claims.

Accordingly the claims as presently amended are believed to be patentable and by this amendment, the application and claims are believed to be in condition for allowance.

If any matters remain the Examiner is invited to call the undersigned and in any case favorable action is respectfully requested.

Respectfully submitted,

/PETER C MICHALOS/
Peter C. Michalos
Reg. No. 28,643
Attorney for Applicants
(845) 359-7700

Dated: September 23, 2008

NOTARO & MICHALOS P.C.
100 Dutch Hill Road, Suite 110
Orangeburg, New York 10962-2100

Customer No. 21706

M:\PAT-AMD\J507-005\J507-005US-AF.wpd